Filing Analysis
Milestone Scientific Inc. held its 2026 Annual Meeting of Stockholders on July 27, 2026. The meeting resulted in the election of five incumbent directors and approval of several key corporate actions, including an increase in authorized shares and an expansion of the equity incentive plan.
🚩 Red Flags
- Significant increase in available shares under the Equity Incentive Plan (from 11.5M to 28.75M), which may lead to future dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on July 27, 2026; quorum represented 50.12% of issued/outstanding shares (44,335,594 shares).
- Five incumbent directors elected: Benedetta Casamento, Neal Goldman, Eric Hines, Dr. Didier Demesmin, and Dr. Dawood Sayed.
- Stockholders approved an amendment to increase authorized common stock from 125,000,000 to 135,000,000 shares.
- Stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing available shares from 11,500,000 to 28,750,000.
- Ratified Grassi & Co. Certified Public Accountants, PC as independent auditors for fiscal year ending Dec 31, 2026.
- Kelly Ulto and Greg Shilling were re-elected to the Board effective July 27, 2026.
Milestone Scientific Inc. announced that three directors have submitted notices to convert their remaining Convertible Bridge Notes into common stock. The conversion is contingent upon the stock maintaining a fair value of at least $0.50 per share.
🚩 Red Flags
- Potential significant dilution for existing shareholders as debt converts into equity.
- Related-party transactions: The notes are held by company directors (insiders).
- The conversion price floor of $0.50 suggests the stock may be trading near or below this level, which could trigger mass dilution if the price recovers slightly.
📋 Key Facts
- Three directors (Benedetta Casamento, Dr. Didier Demesmin, and Neal Goldman) issued Conversion Notices for their remaining Convertible Bridge Notes.
- Total principal amounts to be converted: Ms. Casamento ($116,495.47), Dr. Demesmin ($58,247.73), and Mr. Goldman ($291,238.66).
- Conversion is subject to a price floor of $0.50 per share.
- The conversion becomes effective once the fair value condition is met and compliance with Insider Trading Policy is satisfied.
Milestone Scientific Inc. has restructured compensation agreements with a former CEO/Chairman and appointed new directors, including an Executive Chairman who is also a significant noteholder. The filing details complex amendments to insider compensation and the appointment of two new independent directors.
🚩 Red Flags
- Related-party transaction: Significant compensation restructuring for former CEO Leonard Osser.
- Related-party transaction: Executive Chairman Casamento holds convertible debt and receives supplemental cash/equity compensation.
- Potential dilution risk via Convertible Bridge Notes held by directors with a conversion floor of $0.50.
📋 Key Facts
- Amended agreement with Leonard Osser (former CEO/Chairman) effective April 1, 2026; reduces his annual cash/share compensation by $100,000 while increasing consulting fees by $100,000.
- Osser and wife entered into lock-up agreements restricting share transfers until April 20, 2027.
- Appointed Kelly Ulto (audit expert) and Greg Shilling as new independent directors; both to serve on Audit and Compensation committees.
- Benedetta Casamento appointed Executive Chairman with a $75,000 annual salary and a one-time $100,000 restricted stock grant vesting July 1, 2026.
- Casamento holds $200,000 in Convertible Bridge Notes due April 9, 2028, with a conversion floor of $0.50 per share.
Milestone Scientific Inc. dismissed its independent auditor, CBIZ CPAs P.C., and appointed Grassi & Co., CPAs, P.C. for the 2026 fiscal year. Notably, the outgoing auditor's report for the 2025 fiscal year included a 'going concern' qualification.
🚩 Red Flags
- Going concern qualification in the most recent (2025) audit report.
- Auditor change occurring while the company is under a going concern warning.
- The company is a micro-cap entity (MLSS) which increases the risk associated with financial instability.
📋 Key Facts
- Dismissed CBIZ CPAs P.C. effective May 15, 2026.
- Engaged Grassi & Co., CPAs, P.C. for the fiscal year ending December 31, 2026.
- The 2025 audit report contained an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.
- The company stated there were no disagreements with CBIZ CPAs on accounting principles or practices during the 2025 fiscal year or subsequent interim period.
- CBIZ CPAs had originally become the auditor in April 2025 following its acquisition of Marcum LLP's attest business.
Milestone Scientific Inc. implemented a stock option repricing program for its CEO and SVP, lowering exercise prices to $0.31 and accelerating vesting. The company also established a new performance-based incentive plan with a pool of over 17.2 million shares, representing significant potential dilution for shareholders.
🚩 Red Flags
- Option repricing occurred less than one year after the original grants (August 2025 to April 2026).
- Significant potential dilution from the 17.2M share PRSU pool.
- Acceleration of vesting schedules for top executives concurrent with the price reduction.
- The repricing effectively removes the 'at-risk' nature of the original equity incentives following a decline in stock price.
📋 Key Facts
- CEO Eric Hines and SVP Jason Papes had 4.0 million total options repriced from $0.46-$0.50 down to $0.31 per share.
- Vesting for the repriced options was accelerated from a 3-year schedule to a 2-year schedule, with immediate vesting increased from 200,000 to 500,000 shares per executive.
- A new 2026 Performance Incentive Sub-Plan was created with an aggregate pool of 17,234,635 shares, subject to stockholder approval.
- CEO Eric Hines was granted 5,170,391 PRSUs, while VP Finance Keisha Harcum and SVP Jason Papes each received 3,016,061 PRSUs.
- Performance milestones for the PRSUs include achieving net sales of $11M, $13M, and $15M, reaching a $50M market capitalization, and completing a 'Qualified Acquisition' with >$10M in revenue.
Milestone Scientific Inc. closed a $2.15 million private placement of units at $0.27 per unit, involving significant insider participation and debt conversion. The company amended existing insider bridge notes to lower the conversion floor from $0.50 to $0.27 to facilitate the transaction.
🚩 Red Flags
- Use of proceeds for 'past due accounts payable' indicates immediate liquidity distress.
- Related-party transaction involving directors Neal Goldman, Benedetta Casamento, and Dr. Didier Demesmin.
- Favorable amendment of debt terms for insiders, lowering the conversion price by 46% ($0.50 to $0.27).
- The offering was conducted without a placement agent, suggesting limited institutional interest.
📋 Key Facts
- The company issued 7,962,963 units at $0.27 per unit, each consisting of one share and one warrant.
- Total gross proceeds were $2,150,000, consisting of $1,799,000 in cash and $351,000 in debt conversion.
- Warrants are exercisable at $0.3375 per share for a period of three years.
- Directors and officers purchased $150,000 in units for cash and converted $351,000 of 2025 Convertible Bridge Notes.
- The conversion floor for the insider bridge notes was specifically amended from $0.50 to $0.27 for this placement.
- Proceeds are earmarked for general working capital and the payment of 'past due accounts payable'.
Milestone Scientific Inc. entered into an amendment to its Memorandum of Understanding with Innovest S.p.A. to facilitate a future securities offering. The amendment modifies lock-up provisions and offering definitions related to a significant 11.31% shareholder block.
🚩 Red Flags
- The amendment is a precursor to a likely dilutive securities offering.
- Complex governance structure where a third party (Innovest) holds blockage rights over a major shareholder (BP4 S.r.l.) currently in liquidation.
📋 Key Facts
- On March 31, 2026, the Company amended its MOU with Innovest S.p.A.
- Innovest S.p.A. holds consent/blockage rights over BP4 S.r.l., which owns 11.31% of the Company's common stock.
- The amendment revises the definitions of 'Qualified Offering' and 'Other Locked-Up Parties'.
- The stated purpose of the amendment is to facilitate an upcoming offering by the Company.
Milestone Scientific Inc. has officially increased its authorized common stock from 100,000,000 to 125,000,000 shares following a Certificate of Amendment filed in Delaware. This action follows stockholder approval previously obtained at the company's annual meeting on December 18, 2025.
🚩 Red Flags
- Potential for significant future dilution as the company now has the capacity to issue 25 million additional shares.
📋 Key Facts
- Authorized common stock increased by 25,000,000 shares (a 25% increase in total authorized capacity).
- The Certificate of Amendment was filed and became effective on March 10, 2026.
- The amendment was previously approved by stockholders during the December 18, 2025, annual meeting.
- The filing was made under Item 5.03 (Amendments to Articles of Incorporation).
Milestone Scientific Inc. filed an 8-K/A (Amendment No. 1) to include a previously omitted Memorandum of Understanding (MOU) with Innovest S.p.A. and to correct administrative errors on the cover page.
🚩 Red Flags
- Clerical inconsistency: The exhibit date (June 13, 2026) is listed as being in the future relative to the filing date (February 4, 2026), suggesting a typo in the document text or an error in the amendment's description.
📋 Key Facts
- The filing is an amendment to an original 8-K filed on January 20, 2026.
- Purpose of amendment: To include Exhibit 10.1 (MOU) and fix address/signatory title errors.
- Exhibit 10.1 is an Amended and Restated Memorandum of Understanding between Innovest S.p.A. and Milestone Scientific Inc.
- The MOU date in the exhibit is June 13, 2026 (noting a potential clerical discrepancy as the filing is dated February 2026).
- Stockholder approval for the subject document was obtained on January 15, 2026.
Milestone Scientific Inc. entered into an Amended and Restated Memorandum of Understanding (MOU) with Innovest S.p.A. regarding the lock-up restrictions of BP4 S.r.l., a significant shareholder owning 11.31% of common stock.
🚩 Red Flags
- Significant shareholder (11.31%) has complex conditional distribution rights tied to specific stock price thresholds ($0.50, $0.70, $0.90), which could create significant downward selling pressure if those levels are breached.
📋 Key Facts
- BP4 S.r.l. owns 11.31% of Milestone Scientific Inc.'s outstanding common stock.
- The MOU includes a 12-month lock-up period on BP4 shares following the consummation of a $2.5 million offering by the Company.
- Conditional distribution rights for BP4 shareholders: up to 33.33% can be distributed if stock closes above $0.50 for 10 consecutive days; an additional 33.3% if above $0.70; and the final 33.3% if above $0.90.
- The MOU was approved by BP4's shareholders on January 15, 2026.
Milestone Scientific Inc. held its 2024 Annual Meeting of Stockholders on December 18, 2025. The meeting resulted in the election of six incumbent directors and the approval of an amendment to increase authorized common stock shares.
🚩 Red Flags
- Increase in authorized share count from 100M to 125M may facilitate future equity dilution.
📋 Key Facts
- Annual Meeting held on December 18, 2025.
- Six incumbent directors were elected to serve until the next annual meeting or successors.
- Stockholders approved an amendment to increase authorized Common Stock from 100,000,000 to 125,000,000 shares.
- CBIZCPA P.C. was ratified as independent auditors for the fiscal year ending December 31, 2025.
- Total shares outstanding at record date: 78,628,913; Total shares voted: 48,381,413 (61.53% of issued/outstanding).
Milestone Scientific Inc. announced the resignation of director Leonard A. Osser, effective November 7, 2025. While he is leaving his seat on the Board of Directors, he will maintain involvement through existing employment and consulting agreements.
🚩 Red Flags
- Potential for continued influence/related-party complexity due to the director's ongoing employment and consulting roles despite resigning from the Board.
📋 Key Facts
- Director Leonard A. Osser resigned from the Board of Directors effective November 7, 2025.
- The resignation was characterized by Mr. Osser as an appropriate time to relinquish his position.
- Mr. Osser will remain involved with the company via an employment agreement and a consulting agreement through U.S. Asian Consulting Group, LLC.
Milestone Scientific Inc. received a notice from NYSE American LLC stating the company is non-compliant with continued listing standards under Section(s) 1003(a)(ii) and (iii) of the Company Guide. The company must submit a compliance plan by November 7, 2025, to avoid delisting procedures.
🚩 Red Flags
- Delisting notice from NYSE American
- Requirement to submit a formal plan of compliance to maintain listing status
📋 Key Facts
- Received notice from NYSE American LLC on October 8, 2025.
- Non-compliance identified under Section(s) 1003(a)(ii) and (iii) of the NYSE American Company Guide.
- Deadline to submit a plan of compliance is November 7, 2025.
- Potential delisting procedures could be initiated if a plan is not accepted or if compliance is not met by April 8, 2027.
Milestone Scientific Inc. announced the appointment of Eric Hines as President and Chief Executive Officer, effective July 31, 2025. The filing details his compensation structure, including a base salary and significant stock option grants.
🚩 Red Flags
- The CEO's base salary ($15k-$25k/month) is relatively low for a public company officer, which may reflect current cash preservation efforts or the micro-cap nature of the firm.
- Significant dilution potential from the 2,000,000 share option grant.
📋 Key Facts
- Eric Hines appointed as President and CEO, effective July 31, 2025.
- Initial term compensation: $15,000 per month through December 31, 2025.
- Extended term compensation (starting Jan 1, 2026): $25,000 per month.
- Signing Bonus Options: 2,000,000 shares of Common Stock; 10% vests immediately, 90% vests over three annual installments.
- Hines previously served as President of North America at Ex Libris Group and held leadership roles at NICE Systems.
Milestone Scientific Inc. announced the appointment of Shanth Thiyagalingam as a new independent director on May 14, 2025. The filing also notes a corresponding press release regarding this leadership change.
📋 Key Facts
- Shanth Thiyagalingam appointed as an independent director effective May 14, 2025.
- Thiyagalingam is currently the CEO of PainTEQ.
- Thiyagalingam has extensive medical device industry experience, including roles at Abbott Laboratories, Nevro Corporation, Stryker South Pacific, and St. Jude Medical.
- The appointment was made unanimously by the Board of Directors.
Milestone Scientific Inc. has replaced its independent registered public accounting firm, Marcum LLP, with CBIZ CPAs P.C., effective immediately as of April 22, 2025.
🚩 Red Flags
- Auditor change (though accompanied by a statement of no disagreements, it remains a standard red flag in micro-cap analysis).
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor on April 22, 2025.
- CBIZ CPAs P.C. has been engaged to serve as the new independent auditor for the fiscal year ending December 31, 2025.
- The change follows CBIZ CPAs acquiring Marcum's attest business on November 1, 2024.
- Marcum stated that there were no disagreements regarding accounting principles, financial disclosures, or auditing procedures during the fiscal years 2023 and 2024.
Milestone Scientific Inc. announced the immediate resignation of Director Giandomenico Trombetta on January 12, 2025. The departure is reportedly for personal reasons and not due to any disagreements with the company's operations or finances.
🚩 Red Flags
- Immediate departure of a board member can sometimes signal internal friction, though the filing explicitly denies this.
📋 Key Facts
- Director Giandomenico Trombetta resigned effective immediately on January 12, 2025.
- The resignation was for personal reasons and to attend to other matters.
- The director explicitly stated the resignation was not due to disagreements regarding company operations, finances, policies, or practices.
Milestone Scientific Inc. has finalized a consulting agreement with its outgoing CEO, Arjan Haverhals, effective January 1, 2025. The transition involves Mr. Haverhals moving from his role as CEO to a consultant via his entity, RH Consulting LLC.
🚩 Red Flags
- CEO transition: While structured as a consultancy, the shift from executive to consultant can sometimes mask underlying management instability or be used to facilitate exit packages.
- Potential related-party transaction: The contract is with RH Consulting LLC, an entity owned by the departing CEO.
📋 Key Facts
- Arjan Haverhals will step down as CEO on December 31, 2024.
- A consulting agreement with RH Consulting LLC commences January 1, 2025.
- The annual consulting fee is set at $350,000 ($150,000 for Q1 2025; $66,666 per quarter thereafter).
- Services include sales strategy guidance, reimbursement strategies, international expansion support, and R&D soundboarding.
- The agreement is for an indefinite period with a 90-day termination notice by either party.
Milestone Scientific Inc. announced that CEO Arjan Haverhals will retire effective December 31, 2024, and will transition to a director and consulting role. Board Chairman Neal Goldman has been appointed as Interim CEO while the company searches for a permanent successor.
🚩 Red Flags
- Leadership transition: The appointment of an Interim CEO often indicates a lack of immediate succession planning, though common in micro-caps.
- Increased consulting expense: $350,000 in guaranteed consulting fees for 2025 adds to the company's cash burn/operating expenses.
📋 Key Facts
- CEO Arjan Haverhals to retire on December 31, 2024.
- Haverhals will remain on the Board of Directors and serve as a consultant through 2025.
- Neal Goldman (Chairman of the Board) appointed as Interim CEO effective upon retirement.
- Consulting fees for Haverhals are set at $350,000 for the year 2025 ($150k in Q1; $66,666 per quarter thereafter).
- Haverhals' 2024 bonus will be paid 50% cash and 50% stock.
- The departure is stated to be for personal reasons (family/other interests) and not due to disagreements with management or the Board.
Milestone Scientific Inc. has published an updated investor presentation on its website as of September 27, 2024. This filing is a routine disclosure under Item 7.01 to provide supplemental information to the public.
📋 Key Facts
- The company released an investor presentation via its website (https://tffpharma.com/investors/).
- The presentation was furnished pursuant to Item 7.01 of Form 8-K.
- The filing is dated September 27, 2024.
Milestone Scientific Inc. held its 2024 Annual Meeting of Stockholders on July 16, 2024. The meeting resulted in the election of seven incumbent directors and the ratification of Marcum LLP as the company's independent auditors for the fiscal year ending December 31, 2024.
🚩 Red Flags
- High number of broker non-votes (approx. 26% of total votes cast) for the election of directors.
📋 Key Facts
- Annual Meeting held on July 16, 2024.
- Seven incumbent directors elected to serve until the next annual meeting or successors.
- Marcum LLP ratified as independent auditors for fiscal year ending Dec 31, 2024.
- Total shares outstanding at record date: 77,227,714.
- Total votes cast represented 66.54% of issued and outstanding shares (51,388,906 shares).
- Proposal 1 (Directors) saw significant broker non-votes totaling 20,438,178 shares.
Milestone Scientific Inc. has completed the sale of its unused Net Operating Loss (NOL) and R&D tax credits to Comcast Corporation, resulting in a net cash inflow of $1,983,095. The funds are earmarked for general corporate purposes and working capital subject to state program regulations.
🚩 Red Flags
- Recapture risk: The company faces potential liability for the full face value of the tax credits if it fails to maintain its New Jersey presence or misuses the funds.
- Regulatory compliance burden: Mandatory quarterly reporting to the State of New Jersey for five years increases administrative overhead.
📋 Key Facts
- The Company received net proceeds of $1,983,095 from Comcast Corporation on April 8, 2024.
- The transaction involves the sale of unused Net Operating Loss (NOL) carryover and/or Unused Research and Development (R&D) tax credits.
- The sale was facilitated through the State of New Jersey Emerging Technology and Biotechnology Financial Assistance Program.
- The Company is required to maintain its headquarters or base of operations in New Jersey for five years.
- The Company must provide quarterly reports to the State of New Jersey for a period of five years.
- Funds are subject to recapture up to the face value if continuing obligations regarding office location and allowable expenses are breached.
Milestone Scientific Inc. announced the exercise of an overallotment option by Maxim Group LLC related to a public offering of common stock. This follows a primary offering of 4,765,000 shares at $0.63 per share.
🚩 Red Flags
- Significant dilution: The company is issuing a large volume of common stock (over 5 million shares total including overallotment) at a low price point ($0.63).
- Low share price: Trading near the $1.00 threshold often associated with delisting risks, though no formal notice was issued in this specific filing.
📋 Key Facts
- Underwriter (Maxim Group LLC) exercised the overallotment option on January 12, 2024.
- Overallotment involved 372,110 shares of Common Stock.
- The public offering price was $0.63 per share.
- Net proceeds from the overallotment exercise to the Company were $216,847 after discounts and commissions.